These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 18473714

  • 81. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
    Park JW, Siekmeier R, Lattke P, Merz M, Mix C, Schüler S, Jaross W.
    J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
    [Abstract] [Full Text] [Related]

  • 82. Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients.
    Doser N, Kübli S, Telenti A, Marzolini C, Chave JP, Feihl F, Buclin T, Pannatier A, Darioli R, Nicod P, Waeber B, Mooser V.
    AIDS; 2002 Sep 27; 16(14):1982-3. PubMed ID: 12351967
    [No Abstract] [Full Text] [Related]

  • 83. [Despite coronary intervention, the risk remains high: PCI patients need additional protection].
    MMW Fortschr Med; 2004 Jun 10; 146(24):3. PubMed ID: 15366508
    [No Abstract] [Full Text] [Related]

  • 84.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 85.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 86.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 87. Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition.
    Bandoh T, Mitani H, Niihashi M, Kusumi Y, Kimura M, Ishikawa J, Totsuka T, Sakurai I, Hayashi S.
    J Cardiovasc Pharmacol; 2000 Jan 10; 35(1):136-44. PubMed ID: 10630744
    [Abstract] [Full Text] [Related]

  • 88.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 89.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 90.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 91. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial.
    Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR, Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators.
    Lancet; 2003 Jun 14; 361(9374):2024-31. PubMed ID: 12814712
    [Abstract] [Full Text] [Related]

  • 92.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 93.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 94.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 95. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
    Mendoza S, Gamez R, Mas R, Goicochea E.
    Int J Tissue React; 2003 Jun 14; 25(3):81-9. PubMed ID: 14756189
    [Abstract] [Full Text] [Related]

  • 96. Marked elevation of liver transaminases after high-dose fluvastatin unmasks chronic hepatitis C: safety and re-challenge.
    Chen YW, Lai HW, Wang TD.
    Acta Neurol Taiwan; 2007 Sep 14; 16(3):163-7. PubMed ID: 17966956
    [Abstract] [Full Text] [Related]

  • 97. Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safety.
    Davidson MH.
    Am J Med; 1994 Jun 06; 96(6A):41S-44S. PubMed ID: 8017466
    [Abstract] [Full Text] [Related]

  • 98. Fluvastatin and cancer.
    Mascitelli L, Pezzetta F.
    Int J Clin Pract; 2007 Jan 06; 61(1):168; author reply 168-9. PubMed ID: 17229191
    [No Abstract] [Full Text] [Related]

  • 99.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 100. [Statin-induced rhabdomyolysis and renal failure: also with fluvastatine].
    Lado Lado FL, Rodríguez Moreno C, Cinza Sajurjo S, Durán Parrondo C, Pazo Núñez M, Lois Pernas A, Masa Vázquez L.
    An Med Interna; 2004 May 06; 21(5):235-7. PubMed ID: 15176926
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.